New hope for myeloma: experimental drug QLS32015 faces off against standard care

NCT ID NCT07138209

Recruiting now Disease control Sponsor: Qilu Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Mar 06, 2026 · Last updated May 24, 2026 · Updated 10 times

Summary

This study tests a new drug called QLS32015 against two standard treatments (pomalidomide with dexamethasone, or selinexor with dexamethasone) in people whose multiple myeloma has returned or stopped responding to prior therapy. About 228 adults aged 18 and older will be randomly assigned to receive either QLS32015 alone or one of the standard combinations. The main goal is to see if QLS32015 can delay disease progression or death better than the current options.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

National Clinical Research Center for Blood Diseases
RECRUITING

Tianjin, Tianjin Municipality, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

RELAPSED OR REFRACTORY MULTIPLE MYELOMA